drug development Archives
Treating kidney injury before it happens
May. 23, 2023—Pretreatment of an animal model with a novel compound called PHAD reduced kidney injury, suggesting it may be a good candidate for preventing kidney injury in surgical patients.
A speedier treatment for depression?
Jul. 11, 2022—Vanderbilt researchers used a computer-based search to identify a compound with promise as a new, mechanistically distinct and rapid-acting therapy for major depressive disorder.
Clinical study tests drug that may prevent cancer metastasis
Jul. 8, 2019—A clinical study of a drug that may block cancer metastasis is currently enrolling patients at the Vanderbilt-Ingram Cancer Center.
The arrestin-GPCR connection
Apr. 11, 2019—Understanding details of how arrestins deactivate signaling by G-protein coupled receptors is key to the design of new therapeutics aimed at these cellular "inboxes" that are targeted by up to half of all pharmaceuticals.
Regulating anxiety in the brain
Apr. 28, 2017—Two brain signaling pathways have overlapping functions in regulating anxiety, suggesting that therapeutics aimed at one or the other will impact both.
Protein structure may aid in treating Alzheimer’s disease
Apr. 27, 2017—A new protein structure may guide the development of Alzheimer's therapeutics.
New type of trial shows promise for several cancers
Aug. 20, 2015—Anti-cancer drugs are typically tested on one type of cancer at a time. But an international consortium of cancer investigators, including Vanderbilt-Ingram Cancer Center (VICC) researchers, simultaneously tested an existing therapy in patients with several different forms of cancer that all exhibit the same tumor gene mutation.
